Sun Pharmaceutical Industries lost 4.15% to Rs 778.80 at 9:17 IST on BSE, with the stock sliding in early trade after the company announced Q4 March 2016 results after market hours yesterday, 30 May 2016.
Meanwhile, the S&P BSE Sensex was up 64.23 points or 0.24% at 26,789.83.
On BSE, so far 79,000 shares were traded in the counter as against average daily volume of 2.29 lakh shares in the past two weeks. The stock hit a high of Rs 807.70 and a low of Rs 776.10 so far during the day. The stock had hit a 52-week low of Rs 706.40 on 24 November 2015. The stock had hit a 52-week high of Rs 979 on 29 May 2015.
The large-cap company has equity capital of Rs 240.68 crore. Face value per share is Rs 1.
Sun Pharmaceutical Industries' (Sun Pharma) consolidated net profit rose 92.71% to Rs 1713.69 crore on 16.82% growth in total income to Rs 7599.21 crore in Q4 March 2016 over Q4 March 2015.
Sun Pharma's Managing Director Dilip Shanghvi said that FY 2016 has been a year of consolidation for Sun Pharma. While the company has accrued targeted synergies from the Ranbaxy acquistion, it has also made commensurate investments in building the specialty business in the US, Shanghvi said. These strategic investments will help Sun Pharma drive the sustainable growth of its business, he added.
Sun Pharma's board of directors scheduled a meeting on 23 June 2016 to evaluate a proposal for buyback of equity shares of the company.
Also Read
Sun Pharmaceutical Industries is a specialty generic pharmaceutical company and India's top pharmaceutical company.
Powered by Capital Market - Live News